Hepatocellular carcinoma - Systemic treatments

被引:58
作者
Di Maio, M [1 ]
De Maio, E [1 ]
Perrone, F [1 ]
Pignata, S [1 ]
Daniele, B [1 ]
机构
[1] Natl Canc Inst, Clin Trials Off, I-80131 Naples, Italy
关键词
hepatocellular carcinoma; pharmacologic treatment; chemotherapy; hormonal therapy; interferon;
D O I
10.1097/00004836-200211002-00007
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with increasing incidence in Western countries. Many pharmacologic treatments have been tested against HCC; most of them belong to three categories: chemotherapy, hormone therapy, and immunotherapy. Neither single agent nor combination chemotherapy have demonstrated a clear reproducible advantage in terms of overall survival; therefore, systemic or intraarterial chemotherapy should not be considered as standard strategies for patients with HCC. Tamoxifen and antiandrogen therapy were not effective in prolonging survival when tested in randomized, controlled trials. Promising results have been obtained with octreotide in a small randomized trial, but confirmation studies are needed. Although adoptive immunotherapy was effective in the adjuvant setting, interferon should be further investigated in this setting or investigated as a preventive strategy in cirrhotic patients. On the contrary, interferon does not seem to have a role in advanced disease, where it is tolerated poorly. In the future, innovative and promising therapeutic strategies will be tested in HCC, including new biologic target-based drugs, cyclooxygenase inhibitors, and gene therapy.
引用
收藏
页码:S109 / S114
页数:6
相关论文
共 35 条
[1]  
Bae SH, 2001, CLIN CANCER RES, V7, P1410
[2]   Immunotherapy of hepatocellular carcinoma [J].
Butterfield, LH ;
Ribas, A .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (02) :123-133
[3]  
Di Bisceglie Adrian M., 1998, Hepatology, V28, P1161, DOI 10.1002/hep.510280436
[4]  
Gallo C, 1998, LANCET, V352, P17
[5]   Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European organization for research and treatment of cancer multicentric double-blind trial [J].
Grimaldi, C ;
Bleiberg, H ;
Gay, F ;
Messner, M ;
Rougier, P ;
Kok, TC ;
Cirera, L ;
Cervantes, A ;
De Greve, J ;
Paillot, B ;
Buset, M ;
Nitti, D ;
Sahmoud, T ;
Duez, N ;
Wils, J .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :411-417
[6]  
Hankey, 1973, SEER CANC STAT REV
[7]   Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis [J].
Heathcote, EJ ;
Shiffman, ML ;
Cooksley, WGE ;
Dusheiko, GM ;
Lee, SS ;
Balart, L ;
Reindollar, R ;
Reddy, RK ;
Wright, TL ;
Lin, A ;
Hoffman, J ;
De Pamphilis, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1673-1680
[8]   Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer [J].
Ikeda, K ;
Arase, Y ;
Saitoh, S ;
Kobayashi, M ;
Suzuki, Y ;
Suzuki, F ;
Tsubota, A ;
Chayama, K ;
Murashima, N ;
Kumada, H .
HEPATOLOGY, 2000, 32 (02) :228-232
[9]   Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study [J].
Ikeda, K ;
Saitoh, S ;
Kobayashi, M ;
Suzuki, Y ;
Suzuki, F ;
Tsubota, A ;
Arase, Y ;
Murashima, N ;
Chayama, K ;
Kumada, H .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (04) :406-415
[10]   Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study [J].
Kouroumalis, E ;
Skordilis, P ;
Thermos, K ;
Vasilaki, A ;
Moschandrea, J ;
Manousos, ON .
GUT, 1998, 42 (03) :442-447